Home » The COC Protocol in Glioma

The COC Protocol™ in Glioma



This document provides a brief summary of the current scientific evidence for the adjuvant use of the COC Protocol medications in glioma, including glioblastoma and other high-grade gliomas. A table of all currently ongoing or recently finished clinical trials related to the use of these medications in glioma and other brain tumours is provided in Table 1, which you can find at the end of this article.

For more information regarding your own personal situation, please contact the Care Oncology Clinic on 800-392-1353 or fill out the Patient Eligibility Form.

Patient Eligibility Form


Glioma tumours grow from glial cells in the brain and are the most common type of brain tumour. Low-grade benign gliomas are slower growing and less dangerous than high-grade, aggressive (malignant) gliomas. Glioblastoma multiforme (GBM), a type of malignant astrocytoma, is the most common high-grade brain tumour in adults.

The standard treatment for high-grade glioma is usually surgery, followed by courses of chemotherapy (i.e. temozolomide) and radiation. Much current glioma research is focussed on adding extra (adjuvant) treatments alongside this standard regime in the hope of improving results for patients.

Scientific interest is growing in the use of treatments which target the metabolic pathways of cancer cells (i.e. the processes used by cells to generate energy) to slow or stop the growth of cancers. Care Oncology specialises in using already-licensed (off-label) medications with known anti-metabolic activity to help treat and control cancer. We have developed an adjuvant treatment called the COC Protocol, which combines what we believe to be the most effective metabolically-targeted offlabel medications available.

The COC Protocol as an adjuvant treatment for glioma

This section summarises briefly the existing evidence for effective use of COC Protocol medications in glioma, and of the current clinical trials in this area.


High-grade gliomas like GBM are thought to be very dependent on the cell processes primarily targeted by statins for survival, and fat-soluble ‘lipophilic’ statins like atorvastatin can cross the human BBB relatively easily (1). These qualities, along with the demonstrated ability of statins to slow and suppress glioma cancer cell growth in the lab and in preclinical mouse models makes atorvastatin a good candidate as a repurposed glioma treatment (2).
Several studies show that statins can target and damage glioma cells in a number of different ways, including by increasing programmed and unprogrammed cell death (eg apoptosis and necrosis) (3–5), and reducing cancer cell growth, division, and movement (proliferation and migration)(5–8).

Other lab studies have also shown that statins can help to reduce tumour resistance to other glioma treatments (9–11). One lab study using pitavastatin, a statin similar in profile to atorvastatin, showed that MDR-1, a molecule which is excessively produced in glioma cells in response to treatment and which helps these cells become resistant, is blocked by statins. In this study, statins helped to improve the effectiveness of chemotherapy (12). In a separate lab study, combining statins with an additional metabolically-targeted drug also appeared to increase potency on glioblastoma cells (13).

Most clinical studies for statin use in glioma patients are still ongoing or awaiting results (see Table 1). But completed clinical studies show promise. Early-phase studies from the 1990s, where adult and child patients with solid central nervous system (i.e. brain) tumours and high-grade gliomas took lovastatin or fluvastatin in 3 or 4 weekly cycles, showed that statins were well tolerated. Promising tumour responses were noted in patients with GBM and anaplastic astrocytoma, and study investigators suggested a less cyclical and more constant treatment regime could be more effective (14,15). Patient population studies monitoring survival in large numbers of people who took statins before and during glioblastoma diagnosis and treatment have had inconclusive results, possible due to different study designs (16–18).


Scientific interest in mebendazole as a potential anticancer treatment is relatively new and is mostly based on promising mechanistic studies and compelling reports from case studies in cancer patients (19, 20).

Emerging evidence also suggests that mebendazole may have particularly high levels of activity against cancers of the brain. This is partly because mebendazole is a small, fat-soluble molecule which can easily cross the BBB. It is also thought to work in a similar way to vincristine, a chemotherapy drug currently used for treatment of some types of cancer, including some gliomas (18). Mebendazole is thought to kill cancer cells partly by disrupting special structures inside the cell, called microtubules (21). It can inhibit glioma tumour cell growth in the lab and has been shown to improve survival in preclinical mouse models of glioblastoma (22). In addition, some forms of mebendazole (including the form which is prescribed as part of the COC Protocol) are thought to cross the BBB more readily than vincristine (23), which has led to suggestions that mebendazole should replace vincristine in the treatment of brain tumours (24). In a computer modelling study which looked at 51 different drugs including all chemotherapies used or previously used for treatment of a childhood glioma called DIPG, mebendazole was one of just 8 drugs which was predicted to reach effective concentrations in the brain following systemic (i.e. by mouth or injection) administration (25). Evidence from lab studies also suggests that simultaneous use of microtubule disruptors like mebendazole can help to improve the effectiveness of radiotherapy and temozolomide, two standard glioma treatments (26,27). Numerous clinical trials are now underway to investigate this possibility (see Table 1).


Metformin is not fat soluble but is predicted to cross the BBB using special transporter molecules (28–30). An impressive number of lab studies show metformin can block glioma and glioblastoma cell and tumour growth via a number of different mechanisms, including supressing growth, division and movement of glioma cells (31–33), increasing programmed glioma cell death (34, 35), and blocking growth of new blood vessels (angiogenesis) to glioma tumours (36).

Within the last 5 years scientists have also discovered that metformin can target and disrupt glioblastoma stem cells (37–39). This is important, because these cells are believed to be the initiating cells of a tumour. They can be less responsive to radio- and chemotherapies and are thought to be responsible for tumour regrowth following treatment. Scientists believe control of these cells is key for ensuring long-term survival for patients with glioblastoma (39,40).

Metformin’s real potential in glioma is revealed when metformin is tested in combination with standard therapies or newly-developed anticancer medications. These studies repeatedly show that metformin’s multi-targeted activity against cancer cells and cancer stem cells can potentially improve potency of a combinatorial anticancer treatment regimen. In lab studies, improved anticancer activity (33,41–43) and/or resistance of glioma cells and glioma stem cells to standard therapies such as temozolomide has been overcome using metformin in combination with other drugs (33, 44, 45).

Numerous clinical trials are now underway investigating metformin in combination with other therapies in the treatment of advanced glioblastoma in both adults and children.


Doxycycline is an antibiotic with other extremely valuable properties, including anti-inflammatory and anticancer activity. This gives doxycycline real therapeutic potential in treating a range of other diseases, including cancer (46).

In glioma, a 2007 lab study has shown that doxycycline helps to block tumour cell growth and division and reduces glioma cells’ potential to move and invade other areas of the body (47). Importantly, doxycycline appears to be particularly good at targeting tumour stem cells. Doxycycline can block a process called ‘mitochondrial biogenesis’, which stem cells need to use to make energy for survival and growth. Lab studies show that doxycycline treatment could make glioma stem cells more susceptible to other treatments like radiotherapy (48), and less able to regrow after temozolomide treatment (49). The results of these lab studies are now starting to be replicated in patients- a very recent study has just reported that doxycycline was able to effectively reduce cancer stem cells in patients with early-stage breast cancer (50).

Doxycycline is also well absorbed by the body and is known to cross the BBB effectively (51). These qualities combine to make doxycycline a potentially very powerful anticancer treatment for brain tumours such as glioma (48).

Ongoing clinical research

Table 1 summarises current ongoing or recently completed clinical trials investigating individual metabolically targeted off-label COC Protocol medications in the treatment of brain tumours, including gliomas of all types, glioblastoma, and childhood brain tumours such as medulloblastoma.

It’s notable that whereas most studies are testing just 1 or 2 of these medications in combination with standard treatments, Care Oncology’s own METRICS study (NCT02201381) is currently the only study to investigate the tolerability and effectiveness of a combination of four off-label metabolic treatments (i.e. atorvastatin, mebendazole, metformin, and doxycycline) alongside standard treatments in glioma and other cancers. You can find out more about our study by contacting us.

Table 1: Clinical trials for COC Protocol medications in brain tumours

NCT number

Cancer type


Completion date






Phase 1/2 trial in approx. 20 adults investigating tolerability and effectiveness of metformin and chloroquine in IDH1/2 positive solid tumours

Dec 2016; Results NA


Brain neoplasms

Phase 1 trial in approx. 18 adults investigating safety and effectiveness of treatment of recurrent brain tumours using metabolic manipulation (metformin and low carb diet) combined with radiotherapy

Jul 2018; Results NA


Brain tumour treated with cranial or cranial-spinal radiation

A Phase 3 trial in approx. 24 children with medulloblastoma treated with cranial-spinal radiation investigating effectiveness of added metformin for brain repair

Mar 2018

Results NA


Glioblastoma multiforme

A Phase 2 trial in approx. 50 adults investigating the effectiveness and tolerability of metformin, neo-adjuvant temozolomide and hypo-accelerated radiotherapy followed by adjuvant temozolomide

Dec 2021


Recurrent or refractory glioblastoma

A Phase 2 trial in approx. 108 adults investigating safety and effectiveness of low dose temozolomide plus metformin or placebo

Dec 2018



An early Phase 1 trial in approx. 40 patients investigating the bioavailability (activity in the body) of disulfiram and metformin in glioblastoma

Jun 2019


Glioblastoma multiforme

A Phase I trial in approx. 144 adults investigating the safety and effectiveness of temozolomide plus various combinations of memantine, mefloquine, or metformin for post-radiation therapy of glioblastoma multiforme

Sep 2019


Relapsed or refractory solid tumours and primary brain tumours

A Phase 1 trial in approx. 25 children investigating safety and effectiveness of metformin in combination with vincristine, irinotecan and temozolomide

Dec 2020




A Phase 1 trial in approx. 21 children investigating the safety and effectiveness of fluvastatin and celebrex in low-grade and high grade optico-chiasmatic gliomas

Oct 22


Glioblastoma multiforme

A Phase 2 trial in approx. 36 adults investigating the efficacy and safety of atorvastatin in combination with radiotherapy and temozolomide in glioblastoma

Dec 2016

Results NA


Brain metastases

A Phase 2 trial in approx. 50 adults investigating the efficacy and safety of simvastatin with radiation therapy of brain metastases

Dec 2015;

Trial terminated, results NA



Newly diagnosed high-grade glioma

A Phase 1 trial in approx. 24 adults investigating the tolerability of mebendazole in glioma patients receiving temozolomide

Sep 2020


Childhood glioma

A Phase I/2 trial in approx. 36 children investigating the safety and effectiveness of mebendazole in combination with vincristine, carboplatin and temozolomide or bevacizumab and irinotecan for the treatment of childhood gliomas

Apr 2020


Recurrent/progressive childhood brain tumours

Phase I study in approx. 21 children investigating the safety and effectiveness of mebendazole therapy

Jun 2021

NB: Table accurate according to www.Clinicaltrials.gov website as of October 2018.

Important Notice

Purpose of this article

This article is an overview of some of the scientific and medical published literature concerning the medications which comprise the patented Care Oncology protocol. Care has been taken to select relevant articles supporting the off-label use of these medicines in a clinical setting for the adjunct treatment of cancer. This article does not purport to be a comprehensive review of all the evidence, nor does it capture all of the potential side-effects of such treatment.

This article is for information purposes only and it does NOT constitute medical advice. The medicines discussed herein are available on prescription-only and should not be taken without consultation with your doctor or other professional healthcare provider. Care Oncology doctors will discuss the suitability of these medicines with you and will liaise with your doctor or oncologist to discuss their suitability for you.

You must NOT rely on the information in this article as an alternative to medical advice from your doctor or other professional healthcare provider. If you have any specific questions about any medical matter you should consult your doctor or other professional healthcare provider. If you think you may be suffering from any medical condition you should seek immediate medical attention. You should never delay seeking medical advice, disregard medical advice, or discontinue medical treatment because of information contained in this article.


The copyright in this article is owned by Health Clinics LLC and its licensors.


The Care Oncology (“COC”) Protocol is protected by United States patent US9622982B2 and by various additional international patents.

Reference List
1. Wood WG, Eckert GP, Igbavboa U, Müller WE. STATINS AND NEUROPROTECTION: A PRESCRIPTION TO MOVE THE FIELD FORWARD. Ann N Y Acad Sci [Internet]. 2010 Jun [cited 2018 Oct 8];1199:69–76. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909025/

2. Rundle-Thiele D, Head R, Cosgrove L, Martin JH. Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma. Br J Clin Pharmacol. 2016 Feb;81(2):199–209.

3. Bababeygy SR, Polevaya NV, Youssef S, Sun A, Xiong A, Prugpichailers T, et al. HMG-CoA reductase inhibition causes increased necrosis and apoptosis in an in vivo mouse glioblastoma multiforme model. Anticancer Res. 2009 Dec;29(12):4901–8.

4. Bayat N, Ebrahimi-Barough S, Norouzi-Javidan A, Saberi H, Tajerian R, Ardakan MMM, et al. Apoptotic effect of atorvastatin in glioblastoma spheroids tumor cultured in fibrin gel. Biomed Pharmacother. 2016 Dec;84:1959–66.

5. Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, Yamazoe Y, et al. Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma. J Exp Clin Cancer Res. 2011 Aug 10;30:74.

6. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res. 2000 Aug;20(4):2761–71.

7. Oliveira KA, Dal-Cim T, Lopes FG, Ludka FK, Nedel CB, Tasca CI. Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells. Mol Neurobiol. 2018 Feb;55(2):1509–23.

8. Yongjun Y, Shuyun H, Lei C, Xiangrong C, Zhilin Y, Yiquan K. Atorvastatin suppresses glioma invasion and migration by reducing microglial MT1-MMP expression. J Neuroimmunol. 2013 Jul 15;260(1–2):1–8.

9. Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol. 2008 Oct;90(1):9–17.

10. Chang Y-L, Huang L-C, Chen Y-C, Wang Y-W, Hueng D-Y, Huang S-M. The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines. Int J Biochem Cell Biol. 2017;92:155–63.

11. Hamm R, Zeino M, Frewert S, Efferth T. Up-regulation of cholesterol associated genes as novel resistance mechanism in glioblastoma cells in response to archazolid B. Toxicol Appl Pharmacol. 2014 15;281(1):78–86.

12. Jiang P, Mukthavaram R, Mukthavavam R, Chao Y, Bharati IS, Fogal V, et al. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. J Transl Med. 2014 Jan 17;12:13.

13. Tapia-Pérez JH, Preininger R, Kirches E, Reinhold A, Butzmann J, Prilloff S, et al. Simultaneous Administration of Statins and Pioglitazone Limits Tumor Growth in a Rat Model of Malignant Glioma. Anticancer Res. 2016;36(12):6357–65.

14. Larner J, Jane J, Laws E, Packer R, Myers C, Shaffrey M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol. 1998 Dec;21(6):579–83.

15. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res [Internet]. 1996 Mar 1 [cited 2018 Apr 27];2(3):483–91. Available from: http://clincancerres.aacrjournals.org/content/2/3/483

16. Bhavsar S, Hagan K, Arunkumar R, Potylchansky Y, Grasu R, Dang A, et al. Preoperative statin use is not associated with improvement in survival after glioblastoma surgery. J Clin Neurosci. 2016 Sep;31:176–80.

17. Gaist D, Andersen L, Hallas J, Sørensen HT, Schrøder HD, Friis S. Use of statins and risk of glioma: a nationwide case-control study in Denmark. Br J Cancer. 2013 Feb 19;108(3):715–20.

18. Tan SK, Jermakowicz A, Mookhtiar AK, Nemeroff CB, Schürer SC, Ayad NG. Drug Repositioning in Glioblastoma: A Pathway Perspective. Front Pharmacol [Internet]. 2018 Mar 16 [cited 2018 Oct 8];9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864870/

19. Nygren P, Larsson R. Drug repositioning from bench to bedside: Tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer. Acta Oncologica [Internet]. 2014 Mar [cited 2018 Apr 27];53(3):427–8. Available from: http://www.tandfonline.com/doi/full/10.3109/0284186X.2013.844359

20. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent. Ecancermedicalscience [Internet]. 2014 Jul 10 [cited 2018 Apr 27];8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096024/

21. Lai SR, Castello SA, Robinson AC, Koehler JW. In vitro anti-tubulin effects of mebendazole and fenbendazole on canine glioma cells. Vet Comp Oncol. 2017 Dec;15(4):1445–54.

22. Bai R-Y, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-oncology. 2011 Sep;13(9):974–82.

23. Bai R-Y, Staedtke V, Wanjiku T, Rudek MA, Joshi A, Gallia GL, et al. Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. Clin Cancer Res. 2015 Aug 1;21(15):3462–70.

24. De Witt M, Gamble A, Hanson D, Markowitz D, Powell C, Al Dimassi S, et al. Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors. Mol Med [Internet]. 2017 Apr 5 [cited 2018 Apr 27];23:50–6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403762/

25. El-Khouly FE, van Vuurden DG, Stroink T, Hulleman E, Kaspers GJL, Hendrikse NH, et al. Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates. Front Oncol. 2017;7:254.

26. Kipper FC, Silva AO, Marc AL, Confortin G, Junqueira AV, Neto EP, et al. Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas. Invest New Drugs. 2018 Apr;36(2):323–31.

27. Markowitz D, Ha G, Ruggieri R, Symons M. Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism. Onco Targets Ther. 2017;10:5633–42.

28. Łabuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopień B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacological Reports [Internet]. 2010 Sep [cited 2018 Oct 10];62(5):956–65. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1734114010703571

29. Liang X, Giacomini KM. Transporters Involved in Metformin Pharmacokinetics and Treatment Response. Journal of Pharmaceutical Sciences [Internet]. 2017 Sep [cited 2018 Oct 10];106(9):2245–50. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022354917303519

30. Molenaar RJ, Coelen RJS, Khurshed M, Roos E, Caan MWA, van Linde ME, et al. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours. BMJ Open. 2017 10;7(6):e014961.

31. Liu X, Li J, Schild SE, Schild MH, Wong W, Vora S, et al. Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther [Internet]. 2017 Feb [cited 2018 Apr 27];8(2):73–85. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325211/

32. Seliger C, Meyer A-L, Renner K, Leidgens V, Moeckel S, Jachnik B, et al. Metformin inhibits proliferation and migration of glioblastoma cells independently of TGF-β2. Cell Cycle. 2016 Jul 2;15(13):1755–66.

33. Sesen J, Dahan P, Scotland SJ, Saland E, Dang V-T, Lemarié A, et al. Metformin Inhibits Growth of Human Glioblastoma Cells and Enhances Therapeutic Response. PLoS One [Internet]. 2015 Apr 13 [cited 2018 Sep 5];10(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395104/

34. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007 May;64(10):1290–302.

35. Songthaveesin C, Sa-Nongdej W, Limboonreung T, Chongthammakun S. Combination of metformin and 9-cis retinoic acid increases apoptosis in C6 glioma stem-like cells. Heliyon. 2018 May;4(5):e00638.

36. Elmaci İ, Altinoz MA. A Metabolic Inhibitory Cocktail for Grave Cancers: Metformin, Pioglitazone and Lithium Combination in Treatment of Pancreatic Cancer and Glioblastoma Multiforme. Biochem Genet. 2016 Oct;54(5):573–618.

37. Gritti M, Würth R, Angelini M, Barbieri F, Peretti M, Pizzi E, et al. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current. Oncotarget. 2014 Nov 30;5(22):11252–68.

38. Würth R, Pattarozzi A, Gatti M, Bajetto A, Corsaro A, Parodi A, et al. Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle. 2013 Jan 1;12(1):145–56.

39. Würth R, Barbieri F, Florio T. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int. 2014;2014:126586.

40. Najbauer J, Kraljik N, Németh P. Glioma stem cells: markers, hallmarks and therapeutic targeting by metformin. Pathol Oncol Res. 2014 Oct;20(4):789–97.

41. Aldea MD, Petrushev B, Soritau O, Tomuleasa CI, Berindan-Neagoe I, Filip AG, et al. Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells. J BUON. 2014 Jun;19(2):502–11.

42. Bradford SA, Khan A. Individualizing Chemotherapy using the Anti-Diabetic Drug, Metformin, as an ⠀ œAdjuvant⠀ : An Exploratory Study. Journal of Cancer Science & Therapy [Internet]. 2013 Mar 13 [cited 2018 Sep 5];5(3). Available from: https://www.omicsonline.org/individualizing-chemotherapy-using-the-antidiabetic-drug-metformin-as-an-adjuvant-1948-5956.1000197.php?aid=11581

43. Valtorta S, Dico AL, Raccagni I, Gaglio D, Belloli S, Politi LS, et al. Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models. Oncotarget. 2017 Dec 22;8(68):113090–104.

44. Yang SH, Li S, Lu G, Xue H, Kim DH, Zhu J-J, et al. Metformin treatment reduces temozolomide resistance of glioblastoma cells. Oncotarget. 2016 Nov 29;7(48):78787–803.

45. Yu Z, Zhao G, Xie G, Zhao L, Chen Y, Yu H, et al. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo. Oncotarget. 2015 Oct 20;6(32):32930–43.

46. Bahrami F, Morris DL, Pourgholami MH. Tetracyclines: drugs with huge therapeutic potential. Mini Rev Med Chem. 2012 Jan;12(1):44–52.

47. Wang-Gillam A, Siegel E, Mayes DA, Hutchins LF, Zhou Y-H. Anti-Tumor Effect of Doxycycline on Glioblastoma Cells. 2007;8.

48. Lamb R, Fiorillo M, Chadwick A, Ozsvari B, Reeves KJ, Smith DL, et al. Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy. Oncotarget [Internet]. 2015 Jun 13 [cited 2018 Oct 8];6(16):14005–25. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546447/

49. William D, Walther M, Schneider B, Linnebacher M, Classen CF. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma. PLoS One [Internet]. 2018 Jan 19 [cited 2018 Oct 15];13(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774812/

50. Scatena C, Roncella M, Di Paolo A, Aretini P, Menicagli M, Fanelli G, et al. Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study. Front Oncol [Internet]. 2018 [cited 2018 Oct 15];8. Available from: https://www.frontiersin.org/articles/10.3389/fonc.2018.00452/full

51. Karlsson M, Hammers S, Nilsson-Ehle I, Malmborg AS, Wretlind B. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob Agents Chemother [Internet]. 1996 May [cited 2018 Oct 8];40(5):1104–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC163273/